By Colin Kellaher 



  AstraZeneca PLC and Merck & Co. Monday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of the cancer drug Lynparza in a form of pancreatic cancer. 


  The drugmakers said the recommendation covers Lynparza as monotherapy for the maintenance treatment of adults with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and haven't progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. 


  The indication now awaits approval from the European Commission, which generally follows the CHMP's recommendations. 


  AstraZeneca and Merck in 2017 formed a collaboration to co-develop and co-commercialize Lynparza for multiple cancer types. 


  Write to Colin Kellaher at colin.kellaher@wsj.com